Joel A Sincavage

Array ( [id] => 1544905 [patent_doc_number] => 06444464 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-09-03 [patent_title] => 'Antisense modulation of E2F transcription factor 2 expression' [patent_app_type] => B1 [patent_app_number] => 09/658679 [patent_app_country] => US [patent_app_date] => 2000-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26749 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/444/06444464.pdf [firstpage_image] =>[orig_patent_app_number] => 09658679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1423741 [patent_doc_number] => 06503754 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-01-07 [patent_title] => 'Antisense modulation of BH3 interacting domain death agonist expression' [patent_app_type] => B1 [patent_app_number] => 09/657346 [patent_app_country] => US [patent_app_date] => 2000-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39582 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/503/06503754.pdf [firstpage_image] =>[orig_patent_app_number] => 09657346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1239494 [patent_doc_number] => 06686192 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-02-03 [patent_title] => 'Antisense RNA expression strategies effective against Streptococcus thermophilus bacteriophages' [patent_app_type] => B1 [patent_app_number] => 09/642894 [patent_app_country] => US [patent_app_date] => 2000-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6536 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/686/06686192.pdf [firstpage_image] =>[orig_patent_app_number] => 09642894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 944025 [patent_doc_number] => 06967078 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-11-22 [patent_title] => 'Interaction of Smad6 with Hox proteins and uses thereof' [patent_app_type] => utility [patent_app_number] => 09/631411 [patent_app_country] => US [patent_app_date] => 2000-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5505 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/967/06967078.pdf [firstpage_image] =>[orig_patent_app_number] => 09631411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4357406 [patent_doc_number] => 06255111 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-07-03 [patent_title] => 'Antisense modulation of Her-4 expression' [patent_app_type] => 1 [patent_app_number] => 9/632580 [patent_app_country] => US [patent_app_date] => 2000-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31140 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/255/06255111.pdf [firstpage_image] =>[orig_patent_app_number] => 632580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1374821 [patent_doc_number] => 06558954 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-05-06 [patent_title] => 'Phenotypic conversion of cells mediated by external guide sequences' [patent_app_type] => B1 [patent_app_number] => 09/627562 [patent_app_country] => US [patent_app_date] => 2000-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 17353 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/558/06558954.pdf [firstpage_image] =>[orig_patent_app_number] => 09627562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7645449 [patent_doc_number] => 06472521 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-10-29 [patent_title] => 'Oligonucleotides for the inhibition of human eg5 expression' [patent_app_type] => B1 [patent_app_number] => 09/627122 [patent_app_country] => US [patent_app_date] => 2000-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10129 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/472/06472521.pdf [firstpage_image] =>[orig_patent_app_number] => 09627122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1315160 [patent_doc_number] => 06607915 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-08-19 [patent_title] => 'Antisense inhibition of E2A-Pbx1 expression' [patent_app_type] => B1 [patent_app_number] => 09/624945 [patent_app_country] => US [patent_app_date] => 2000-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14562 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/607/06607915.pdf [firstpage_image] =>[orig_patent_app_number] => 09624945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1534906 [patent_doc_number] => 06489307 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-12-03 [patent_title] => 'Antisense compositions targeted to 1-adrenoceptor-specific mRNA and methods of use' [patent_app_type] => B1 [patent_app_number] => 09/614034 [patent_app_country] => US [patent_app_date] => 2000-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 44479 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/489/06489307.pdf [firstpage_image] =>[orig_patent_app_number] => 09614034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1549269 [patent_doc_number] => 06346374 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-02-12 [patent_title] => 'Nucleic acid molecules encoding GLUTX and uses thereof' [patent_app_type] => B1 [patent_app_number] => 09/610417 [patent_app_country] => US [patent_app_date] => 2000-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 28503 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/346/06346374.pdf [firstpage_image] =>[orig_patent_app_number] => 09610417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1005430 [patent_doc_number] => 06906026 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-06-14 [patent_title] => 'Methods for treating conditions associated with the accumulation of excess extracellular matrix' [patent_app_type] => utility [patent_app_number] => 09/869820 [patent_app_country] => US [patent_app_date] => 2000-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14158 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/906/06906026.pdf [firstpage_image] =>[orig_patent_app_number] => 09869820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1408217 [patent_doc_number] => 06528310 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-03-04 [patent_title] => 'Cancer control' [patent_app_type] => B1 [patent_app_number] => 09/602868 [patent_app_country] => US [patent_app_date] => 2000-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 12516 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/528/06528310.pdf [firstpage_image] =>[orig_patent_app_number] => 09602868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1138818 [patent_doc_number] => 06780850 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-08-24 [patent_title] => 'Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood' [patent_app_type] => B1 [patent_app_number] => 09/599220 [patent_app_country] => US [patent_app_date] => 2000-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 10990 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/780/06780850.pdf [firstpage_image] =>[orig_patent_app_number] => 09599220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4349363 [patent_doc_number] => 06291230 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-09-18 [patent_title] => 'Galk promoter' [patent_app_type] => 1 [patent_app_number] => 9/595718 [patent_app_country] => US [patent_app_date] => 2000-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10149 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/291/06291230.pdf [firstpage_image] =>[orig_patent_app_number] => 595718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1500090 [patent_doc_number] => 06485973 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-11-26 [patent_title] => 'Oligonucleotides specific for the marORAB operon' [patent_app_type] => B1 [patent_app_number] => 09/596390 [patent_app_country] => US [patent_app_date] => 2000-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9143 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/485/06485973.pdf [firstpage_image] =>[orig_patent_app_number] => 09596390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1156809 [patent_doc_number] => 06762169 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-07-13 [patent_title] => 'Ligand-conjugated oligomeric compounds' [patent_app_type] => B1 [patent_app_number] => 09/594387 [patent_app_country] => US [patent_app_date] => 2000-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 35444 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/762/06762169.pdf [firstpage_image] =>[orig_patent_app_number] => 09594387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1212522 [patent_doc_number] => 06709860 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-03-23 [patent_title] => 'Animal model' [patent_app_type] => B1 [patent_app_number] => 09/587945 [patent_app_country] => US [patent_app_date] => 2000-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 33 [patent_no_of_words] => 19939 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/709/06709860.pdf [firstpage_image] =>[orig_patent_app_number] => 09587945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 953972 [patent_doc_number] => 06958386 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-10-25 [patent_title] => 'MUM-1 protein expressed by multiple myeloma-related gene' [patent_app_type] => utility [patent_app_number] => 09/585023 [patent_app_country] => US [patent_app_date] => 2000-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 23 [patent_no_of_words] => 11800 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/958/06958386.pdf [firstpage_image] =>[orig_patent_app_number] => 09585023 [rel_patent_id] =>[rel_patent_doc_number] =>)